Small Molecule vs Monoclonal Antibody — Oncology Deal Terms Comparison
Market Analysis
In oncology, Small Molecule and Monoclonal Antibody represent two of the most actively transacted modalities. At Phase 2, Small Molecule deals carry a median total deal value of $1.6B with $258M upfront, compared to $1.7B total value and $266M upfront for Monoclonal Antibody. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Small Molecule development milestones average $345M versus $355M for Monoclonal Antibody. Commercial milestones are $483M for Small Molecule and $497M for Monoclonal Antibody. Royalty rates range from 11.8%-19.3% for Small Molecule and 11.9%-19.5% for Monoclonal Antibody.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Small Molecule and Monoclonal Antibody deal terms compare in oncology?
Which modality commands higher royalty rates: Small Molecule or Monoclonal Antibody?
How do milestone structures differ between Small Molecule and Monoclonal Antibody?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.